Published in Cancer Weekly, July 4th, 2000
CpG DNA molecules are novel immune stimulants that activate the immune system and may enhance the body's ability to fight cancer. Through the collaboration, Ludwig researchers will conduct early clinical studies designed to examine the safety and potential utility of CpG DNA-based products as stand-alone treatments for cancer, as well as in combination with several of Ludwig's proprietary tumor-specific antigens...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.